Pharma-Bio Serv Announces Full Year Results and Special Dividend

Rhea-AI Summary

Pharma-Bio Serv (OTCQB:PBSV) reported fiscal year ended October 31, 2025 revenue of approximately $9.0 million, down roughly $0.5 million versus prior year, and a net loss of approximately $0.1 million, an improvement of about $0.7 million year-over-year. The Board approved a Special Dividend of $0.075 per share, payable on or about March 20, 2026, to shareholders of record at the close of business on February 27, 2026. Management said it rationalized services and clients, realigned the organization, and is targeting selective opportunities in Latin America and high-value segments in Europe to support improved performance in 2026.

Positive

• Board approved a $0.075 per-share Special Dividend payable March 20, 2026
• Net loss improved by approximately $0.7 million year-over-year to about $0.1 million

Negative

• Revenue declined to approximately $9.0 million, down about $0.5 million versus prior year
• Company reported a net loss of approximately $0.1 million for fiscal 2025

DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2025 were approximately $9.0 million, a decrease of approximately $0.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2025 was reported of approximately $0.1 million, an improvement of approximately $0.7 million when compared to last year.

Also, Pharma-Bio Serv today announced the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about March 20, 2026 to shareholders of record at the close of business on February 27, 2026.

"Throughout 2025, we remained focused on strengthening the fundamentals of the business by continuing to rationalize our portfolio of services and clients, as well as aligning our organizational structure with our strategic priorities. These actions were intended to reinforce operational discipline and position the Company for more consistent performance. Entering the new fiscal year, we believe we are better aligned with markets where our capabilities are most differentiated, including selective opportunities in Latin America and high-value segments in Europe. We believe that the initiatives undertaken during the past year, combined with a more streamlined cost structure, will support a favorable shift in our trajectory during 2026," said Mr. Sanchez, Chief Executive Officer.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's most recent Annual Report on Form 10-K, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv, Inc.

View the original press release on ACCESS Newswire

FAQ

What dividend did Pharma-Bio Serv (PBSV) announce for March 2026?

The company approved a $0.075 per-share Special Dividend payable on or about March 20, 2026. According to the company, shareholders of record at the close of business on February 27, 2026 will receive the dividend.

What were Pharma-Bio Serv (PBSV) full-year 2025 revenues and how did they change?

Pharma-Bio Serv reported full-year revenue of approximately $9.0 million, down about $0.5 million year-over-year. According to the company, this reflects portfolio rationalization and client adjustments during 2025.

Did Pharma-Bio Serv (PBSV) report a profit or loss for fiscal 2025?

The company reported a net loss of approximately $0.1 million for the year ended October 31, 2025. According to the company, this represented an improvement of about $0.7 million versus the prior year.

How does Pharma-Bio Serv (PBSV) expect to improve performance in 2026?

Management said it will focus on streamlined services and selective markets to improve results in 2026. According to the company, efforts target Latin America and high-value European segments after portfolio and cost rationalization.